Human Urotensin II in the plasma of anephric subjects

Mosenkis, Ari; Danoff, Theodore M.; Aiyar, Nambi; Bazeley, Jonathan; Townsend, Raymond R.

doi:10.1093/ndt/gfl697

Cited by 6 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UII can also be synthesized in non-renal tissue, such as the heart (6). Some researchers have shown that UII may play a cardioprotective role in patients with ischemic heart disease and chronic renal failure (7,8).…”

Section: Introductionmentioning

confidence: 99%

Urotensin II levels in patients with chronic kidney disease and kidney transplants

Hurşitoğlu¹,

Tükek²,

Çıkrıkçıoğlu³

et al. 2011

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

Objective. Urotensin II is a potent vasoactive peptide that has been implicated in the pathophysiology of many diseases. There is no study reporting the role and level of this peptide in recipients of kidney transplant. So we aimed to study the plasma levels of urotensin II in this group of patients.Methods. Plasma urotensin II levels were analyzed in 110 subjects, who were divided into three groups: group 1 (35 kidney transplant recipients), group 2 (36 patients with chronic kidney disease), and group 3 (39 healthy controls).Results. Analysis of logarithmic transformation of urotensin II, i.e. log (urotensin II × 1000) levels, with a one-way analysis of variance yielded a P value of 0.001. Post-hoc analysis showed significantly higher log (urotensin II × 1000) levels in group 1 than groups 2 and 3 (P = 0.001 and 0.017, respectively). One of the important features of the subjects of this group was that they were taking immunosuppressive drugs because of renal transplantation.Conclusions. High urotensin II levels in recipients of kidney transplants could be drug-related (immunosuppressive drugs) and may be of practical importance that may be used to improve the long-term outcome of the patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Urotensin II levels in patients with chronic kidney disease and kidney transplants

Hurşitoğlu¹,

Tükek²,

Çıkrıkçıoğlu³

et al. 2011

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

show abstract

“…A high concentration of UII and its receptors has been demonstrated in the kidneys of mice, monkeys [25], humans [26,27], and CKD models of rat studies [28]. These investigations have lead to the thinking that UII is synthesized, secreted and cleared by the kidneys [29], although our previous experience in two surgically anephric patients indicates that the UII must be synthesized in non-renal tissues [30].…”

Section: Introductionmentioning

confidence: 99%

Renal impairment, hypertension and plasma urotensin II

Mosenkis

Kallem

Danoff

et al. 2010

Nephrology Dialysis Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…UII-like immunoreactive staining has been reported in renal capillary endothelial cells from control subjects (Shenouda et al 2002), and these cells may be a potential source of increased circulating concentrations of UII detected in patients with renal dysfunction (Totsune et al 2001). It is interesting to note that there was a trend for increased plasma UII concentrations in two patients who had undergone previous (6 months since removal of tissue) bilateral nephrectomy compared to 29 patients undergoing hemodialysis for end-stage renal disease (Mosenkis et al 2007), underlining the importance of nonrenal tissues as additional sources of UII.…”

Section: What Is the Source Of Uii?mentioning

confidence: 99%

Urotensin II in cardiovascular regulation

Russell¹

2008

VHRM

View full text Add to dashboard Cite

Cardiovascular function is modulated by neuronal transmitters, circulating hormones, and factors that are released locally from tissues. Urotensin II (UII) is an 11 amino acid peptide that stimulates its' obligatory G protein coupled urotensin II receptors (UT) to modulate cardiovascular function in humans and in other animal species, and has been implicated in both vasculoprotective and vasculopathic effects. For example, tissue and circulating concentrations of UII have been reported to increase in some studies involving patients with atherosclerosis, heart failure, hypertension, preeclampsia, diabetes, renal disease and liver disease, raising the possibility that the UT receptor system is involved in the development and/or progression of these conditions. Consistent with this hypothesis, administration of UT receptor antagonists to animal models of cardiovascular disease have revealed improvements in cardiovascular remodelling and hemodynamics. However, recent studies have questioned this contributory role of UII in disease, and have instead postulated a protective effect on the cardiovascular system. For example, high concentrations of circulating UII correlated with improved clinical outcomes in patients with renal disease or myocardial infarction. The purpose of this review is to consider the regulation of the cardiovascular system by UII, giving consideration to methodologies for measurement of plasma concentrations, sites of synthesis and triggers for release.

show abstract

Human Urotensin II in the plasma of anephric subjects

Cited by 6 publications

References 5 publications

Urotensin II levels in patients with chronic kidney disease and kidney transplants

Urotensin II levels in patients with chronic kidney disease and kidney transplants

Renal impairment, hypertension and plasma urotensin II

Urotensin II in cardiovascular regulation

Contact Info

Product

Resources

About